Alimentary Pharmacology & Therapeutics

Review article: interactions between genotype and response to therapy in inflammatory bowel diseases
pp. 1403-1412(10)
Authors: HERRLINGER, K. R.; JEWELL, D. P.

Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients
pp. 1413-1422(10)
Authors: FABRIZI, F.; LUNGHI, G.; DIXIT, V.; MARTIN, P.

Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial
pp. 1423-1430(8)
Authors: ROSSIGNOL, J.-F.; EL-GOHARY, Y. M.

Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors
pp. 1431-1438(8)
Authors: THOMSEN, R. W.; RIIS, A.; CHRISTENSEN, S.; MCLAUGHLIN, J. K.; SØRENSEN, H. T.

An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion
pp. 1439-1444(6)
Authors: MOROCUTTI, A.; MERROUCHE, M.; BJAALAND, T.; HUMPHRIES, T.; MIGNON, M.

A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study
pp. 1445-1451(7)
Authors: MIKI, M.; ADACHI, K.; AZUMI, T.; KOSHINO, K.; FURUTA, K.; KINOSHITA, Y.

Corpus-predominant gastritis as a risk factor for false-negative ¹³C-urea breath test results
pp. 1453-1460(8)
Authors: CAPURSO, G.; CARNUCCIO, A.; LAHNER, E.; PANZUTO, F.; BACCINI, F.; FAVE, G. D.; ANNIBALE, B.

Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial
pp. 1461-1468(8)
Authors: LIONETTI, E.; MINIELLO, V. L.; CASTELLANETA, S. P.; MAGISTÁ, A. M.; DE CANIO, A.; MAUROGIOVANNI, G.; IERARDI, E.; CAVALLO, L.; FRANCAVILLA, R.

Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures
pp. 1469-1474(6)
Authors: GISBERT, J. P.; GISBERT, J. L.; MARCOS, S.; MORENO-OTERO, R.; PAJARES, J. M.

Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
pp. 1475-1481(7)
Authors: LEVI, Z.; ROZEN, P.; HAZAZI, R.; VILKIN, A.; WAKED, A.; MAOZ, E.; BIRKENFELD, S.; NIV, Y.

Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C
pp. 1483-1493(11)
Authors: LIN, W.-A.; TARN, Y.-H.; TANG, S.-L.

Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma
pp. 1495-1501(7)
Authors: BALDAN, A.; MARINO, D.; DE GIORGIO, M.; ANGONESE, C.; CILLO, U.; D'ALESSANDRO, A.; MASOTTO, A.; MASSANI, M.; MAZZUCCO, M.; MIOLA, E.; NERI, D.; PACCAGNELLA, D.; PIVETTA, G.; STELLATO, A.; TOMMASI, L.; TREMOLADA, F.; TUFANO, A.; ZANUS, G.; FARINATI, F.

Bilirubin and colorectal cancer
pp. 1503-1504(2)
Author: Vitek, L.

Bilirubin and colorectal cancer: authors' reply
pp. 1504-1504(1)
Authors: Ioannou, G. N.; Liou, I. W.; Weiss, N. S.

Excellent therapy for Helicobacter pylori infection
pp. 1505-1505(1)
Author: Bateson, M. C.

Corrigendum
pp. 1506-1506(1)